First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer-Reference-Cited by-同舟云学术

First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer

Published:2013-10-29 Issue:10 Volume:109 Page:2579-2586
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Bianchini D,Omlin A,Pezaro C,Lorente D,Ferraldeschi R,Mukherji D,Crespo M,Figueiredo I,Miranda S,Riisnaes R,Zivi A,Buchbinder A,Rathkopf D E,Attard G,Scher H I,de Bono J,Danila D C

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/bjc2013619.pdf

Reference27 articles.

1. Attard G, Richards J, de Bono JS (2011) New strategies in metastatic prostate cancer: targeting the androgen receptor signaling pathway. Clinical Cancer Res 17 (7): 1649–1657.

2. Balbas MD, Evans MJ, Hosfield DJ, Wongvipat J, Arora VK, Watson PA, Chen Y, Greene GL, Shen Y, Sawyers CL (2013) Overcoming mutation-based resistance to antiandrogens with rational drug design. Elife 2: e00499.

3. Chi KN, Eisenhauer E, Fazli L, Jones EC, Goldenberg SL, Powers J, Tu D, Gleave ME (2005) A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 97 (17): 1287–1296.

4. Chi KN, Hotte SJ, Ellard S, Gingerich JR, Joshua AM, Yu EY, Gleave ME (2012) A randomized phase II study of OGX-427 plus prednisone (P) versus P alone in patients (pts) with metastatic castration resistant prostate cancer (CRPC). J Clin Oncol 30, (suppl; abstr 4514).

5. Chi KN, Hotte SJ, Yu EY, Tu D, Eigl BJ, Tannock I, Saad F, North S, Powers J, Gleave ME, Eisenhauer EA (2010) Randomized phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 28 (27): 4247–4254.

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current and emerging approaches to noncompetitive AR inhibition;Medicinal Research Reviews;2023-04-16

2. Locked nucleic acid (LNA): A modern approach to cancer diagnosis and treatment;Experimental Cell Research;2023-02

3. Nano drug delivery systems for antisense oligonucleotides (ASO) therapeutics;Journal of Controlled Release;2022-12

4. Antisense oligonucleotides targeting ORF1b block replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2);Frontiers in Microbiology;2022-10-26

5. The androgen receptor-targeted proteolysis targeting chimera and other alternative therapeutic choices in overcoming the resistance to androgen deprivation treatment in prostate cancer;Clinical and Translational Oncology;2022-10-06